Premium
Diannexin, a Novel Annexin V Homodimer, Protects Rat Liver Transplants Against Cold Ischemia‐Reperfusion Injury
Author(s) -
Shen X.D.,
Ke B.,
Zhai Y.,
Tsuchihashi S.I.,
Gao F.,
Duarte S.,
Coito A.,
Busuttil R. W.,
Allison A. C.,
KupiecWeglinski J. W.
Publication year - 2007
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2007.01967.x
Subject(s) - medicine , annexin , reperfusion injury , viaspan , platelet , tunel assay , transplantation , ischemia , apoptosis , annexin a5 , phosphatidylserine , liver transplantation , cold storage , platelet activation , immunology , andrology , pharmacology , endocrinology , flow cytometry , chemistry , biology , phospholipid , biochemistry , immunohistochemistry , membrane , horticulture
Ischemia/reperfusion injury (IRI) remains an important problem in clinical transplantation. Following ischemia, phosphatidylserine (PS) translocates to surfaces of endothelial cells (ECs) and promotes the early attachment of leukocytes/platelets, impairing microvascular blood flow. Diannexin, a 73 KD homodimer of human annexin V, binds to PS, prevents attachment of leukocytes/platelets to EC, and maintains sinusoidal blood flow. This study analyzes whether Diannexin treatment can prevent cold IRI in liver transplantation. Rat livers were stored at 4°C in UW solution for 24 h, and then transplanted orthotopically (OLT) into syngeneic recipients. Diannexin (200 μg/kg) was infused into: (i) donor livers after recovering and before reperfusion, (ii) OLT recipients at reperfusion and day +2. Controls consisted of untreated OLTs. Both Diannexin regimens increased OLT survival from 40% to 100%, depressed sALT levels, and decreased hepatic histological injury. Diannexin treatment decreased TNF‐α, IL‐1β, IP‐10 expression, diminished expression of P‐selectin, endothelial ICAM‐1, and attenuated OLT infiltration by macrophages, CD4 cells and PMNs. Diannexin increased expression of HO‐1/Bcl‐2/Bcl‐xl, and reduced Caspase‐3/TUNEL+ apoptotic cells. Thus, by modulating leukocyte/platelet trafficking and EC activation in OLTs, Diannexin suppressed vascular inflammatory responses and decreased apoptosis. Diannexin deserves further exploration as a novel agent to attenuate IRI, and thereby improve OLT function/increase organ donor pool.